3 results
To determine whether treatment with RAD001 10 mg/d plus Sandostatin LAR® prolongs the progression free survival (PFS) compared to treatment with Sandostatin LAR® alone in patients with advanced carcinoid tumor.
Primary: To allow continued use of everolimus to patients receiving everolimus in a Novartis-sponsoredstudy which has reached its objectives and who are benefitting from treatment with everolimus as defined in the parent protocolSecondary: To…
3.1 Primary Objective• Feasibility of Magtrace® as a tracer in SLN sampling in early stage EOC.3.2 Secondary Objectives• Comparison of detection rate between MagTrace® and 99mTco In the general cohorto In primary staging laparotomyo In secondary…